Prnewswire·2026-03-10 20:01Core Insights - Neurocrine Biosciences, Inc. will participate in the Stifel 2026 Virtual CNS Forum on March 17, 2026, at 4:30 PM EST, with a live webcast available on their website [1] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on developing treatments for neurological, psychiatric, endocrine, and immunological disorders [1] - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, with some treatments developed in collaboration with AbbVie [1] - Neurocrine has a robust pipeline with multiple compounds in mid- to late-phase clinical development across its core therapeutic areas [1] - The company has been applying insights into neuroscience for three decades to address complex conditions and aims to relieve suffering for patients with significant needs [1]